Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Danorrnon Aug 05, 2021 10:39am

165 Views

Post# 33654487

There is a ton of articles to read of interested

https://www.ncbi.nlm.nih.gov/books/NBK548159/ https://www.researchgate.net/publication/343678062_Hepatotoxicity_and_Changes_in_Liver_Enzymes_Due_to_Use_of_Non-Steroidal_Anti_Inflammatory_Drugs_NSAIDs_in_Non-Traumatic_Musculoskeletal_Painful_Disorders

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?